Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,075,982
  • Shares Outstanding, K 79,718
  • Annual Sales, $ 0 K
  • Annual Income, $ -252,060 K
  • EBIT $ -306 M
  • EBITDA $ -319 M
  • 60-Month Beta -0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.70

Options Overview Details

View History
  • Implied Volatility 74.05% ( -2.18%)
  • Historical Volatility 35.32%
  • IV Percentile 74%
  • IV Rank 17.77%
  • IV High 293.20% on 01/16/25
  • IV Low 26.69% on 08/16/24
  • Put/Call Vol Ratio 0.28
  • Today's Volume 281
  • Volume Avg (30-Day) 1,286
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 34,874
  • Open Int (30-Day) 32,228

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.95
  • Number of Estimates 3
  • High Estimate -0.94
  • Low Estimate -0.97
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -17.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.04 +3.92%
on 07/10/25
57.35 -9.33%
on 06/27/25
-2.52 (-4.62%)
since 06/10/25
3-Month
34.18 +52.14%
on 04/11/25
57.35 -9.33%
on 06/27/25
+17.18 (+49.34%)
since 04/10/25
52-Week
21.34 +143.67%
on 01/14/25
58.40 -10.96%
on 01/27/25
+28.00 (+116.67%)
since 07/10/24

Most Recent Stories

More News
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

AKRO : 52.00 (+1.70%)
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

AKRO : 52.00 (+1.70%)
Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

VRTX : 479.53 (+0.12%)
AKRO : 52.00 (+1.70%)
REGN : 559.76 (+1.30%)
XBI : 88.38 (+0.58%)
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

AKRO : 52.00 (+1.70%)
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

AKRO : 52.00 (+1.70%)
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

AKRO : 52.00 (+1.70%)
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

AKRO : 52.00 (+1.70%)
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

AKRO : 52.00 (+1.70%)
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

AKRO : 52.00 (+1.70%)
3 Mid-Caps Worth Watching Closely in March 

Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation.

AKRO : 52.00 (+1.70%)
HEES : 94.64 (-0.63%)
OKLO : 55.45 (+2.82%)
HRI : 149.06 (+3.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which...

See More

Key Turning Points

3rd Resistance Point 54.73
2nd Resistance Point 53.40
1st Resistance Point 52.70
Last Price 52.00
1st Support Level 50.67
2nd Support Level 49.34
3rd Support Level 48.64

See More

52-Week High 58.40
Last Price 52.00
Fibonacci 61.8% 44.24
Fibonacci 50% 39.87
Fibonacci 38.2% 35.50
52-Week Low 21.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar